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A noniterative sample size procedure for tests
based on t distributions
Yongqiang Tang
A noniterative sample size procedure is proposed for a general hypothesis test based on the t distribution by
modifying and extending Guenther’s (1981) approach for the one sample and two sample t tests. The generalized
procedure is employed to determine the sample size for treatment comparisons using the analysis of covariance
(ANCOVA) and the mixed effects model for repeated measures (MMRM) in randomized clinical trials. The sample
size is calculated by adding a few simple correction terms to the sample size from the normal approximation to
account for the nonnormality of the t statistic and lower order variance terms, which are functions of the covariates
in the model. But it does not require specifying the covariate distribution. The noniterative procedure is suitable for
superiority tests, noninferiority tests and a special case of the tests for equivalence or bioequivalence, and generally
yields the exact or nearly exact sample size estimate after rounding to an integer. The method for calculating the
exact power of the two sample t test with unequal variance in superiority trials is extended to equivalence trials. We
also derive accurate power formulae for ANCOVA and MMRM, and the formula for ANCOVA is exact for normally
distributed covariates. Numerical examples demonstrate the accuracy of the proposed methods particularly in
small samples. Copyright c© 2015 John Wiley & Sons, Ltd.
Keywords: Analysis of covariance; Crossover trial; Exact power; Kenword-Roger variance; Mixed effects
models for repeated measures; Superiority, noninferiority, equivalence and bioequivalence
trials
1. Introduction
Many common tests for continuous outcomes are based on the t test statistics. Examples include the one sample t test,
two sample t test, and tests associated with the analysis of covariance (ANCOVA) and linear mixed effects models for
repeated measurement (MMRM). The sample size determination is critical to ensure the success of a clinical trial since an
underpowered study has less chance to detect an important treatment effect, whereas the samples that are too large may
waste time and resources [1]. Sample size calculation for the t tests is usually based on the normal approximation, and/or
the asymptotic variance of the treatment effect [1, 2, 3, 4]. These methods work well in large clinical trials, but generally
underestimate the size in small trials because the normal distribution cannot adequately approximate the t distribution, and
the asymptotic variance underestimates the true variance of the estimated effect in ANCOVA and MMRM [5].
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In this article, we propose a noniterative sample size procedure for a test based on the t distribution in finite samples.
The procedure generalizes Guenther’s [6] method for the one sample t test and two sample t tests with equal variances,
which is extended to the two sample t test with unequal variances by Schouten [7]. In Guenther’s approach, the normal
approximation is improved by adding a correction factor. As indicated by Schouten [7], Guenther’s approach still
underestimates the required sample size. We also propose a slightly more conservative sample size estimate by introducing
one lower order correction term to Guenther’s formula. For ANCOVA and MMRM, additional correction terms are added
to account for lower order variance terms, which are functions of covariates included in the regression. There is limited
information about the covariate distribution at the design stage due to the inclusion/ exclusion criteria imposed on the
patients. But there is no need to specify the covariate distribution.
The proposed sample size method is suitable for superiority trials, noninferiority (NI) trials and a special case of the
trials for demonstrating clinical equivalence or bioequivalence (BE). In Section 2, we present the noniterative sample size
procedure for a number of t tests commonly used in the analysis of superiority trials, and assess their performance by
simulation. We derive accurate power formulae for ANCOVA and MMRM, and the formula for ANCOVA is exact if the
covariates are normally distributed. Section 3 studies the power and sample size determination for the NI, equivalence
and BE trials, where we also obtain the exact power for the two sample t test with unequal variance in equivalence trials.
Numerical examples indicate that the sample size estimate (after rounding to an integer) from the noniterative procedure
is often exact and identical to that obtained by numerically inverting the power equation.
Throughout the paper, we let t(f, λ) denote the t distribution with f degrees of freedom (d.f.) and noncentrality
parameter λ, t(f) the central t distribution, F (f1, f2, λ) the F distribution with f1 and f2 d.f. and noncentrality parameter
λ, and F (f1, f2) the central F distribution. Let zp and tf,p be respectively the pth percentiles of the normal N(0, 1) and
central t(f) distributions. Let Φ(·) be the cumulative distribution function of N(0, 1). Let x⊗2 = xx′.
2. A generalized sample size procedure for t tests in superiority trials
2.1. The generalized sample size procedure
Let τ be the parameter of interest. For example, τ is the difference in the mean response between two treatment groups
in comparative clinical trials. Let τˆ be the point estimate of τ , n−1V the associated variance, and Vˆ the estimate
of the variance parameter V . Assume that τˆ and Vˆ are independent, and f Vˆ /V ∼ χ2f . Then var(Vˆ ) = 2V 2/f and
var(
√
Vˆ ) = V/(2f). Suppose we are interested in the test of equality
H0 : τ = τ0 versus H1 : τ = τ1. (1)
In comparative superiority trials, the purpose is to show that the test treatment is better than the control, and τ0 is usually
set to 0. The test statistic T = (τˆ − τ0)/
√
n−1Vˆ ∼ t(f) underH0. The null hypothesisH0 is rejected if |T | > tf,1−α/2.
Since T 2 ∼ F (1, f, n(τ1 − τ0)2/V ) underH1, the power of the two-sided test (1) is
P = Pr
[
F (1, f,
(τ1 − τ0)2
n−1V
) > t2f,1−α2
]
= Pr
[
t(f,
|τ1 − τ0|√
n−1V
) > tf,1−α
2
]
+ Pr
[
t(f,
|τ1 − τ0|√
n−1V
) < −tf,1−α
2
]
, (2)
which can be well approximated by the power of the one-sided test if τ1 is not too close to τ0 to be of practical interest
P ≈ Pr
[
t(f,
|τ1 − τ0|√
n−1V
) > tf,1−α
2
]
. (3)
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The sample size is often obtained by numerically inverting Equation (2) or by normal approximation. The normal
approximation is poor if the resulting sample size n˜ is small
n˜ =
(z1−α/2 + zP )2 V
(τ1 − τ0)2 . (4)
Below we describe a generalization of Guenther’s procedure [6] to the sample size determination for test (1). In this
approach, the sample size is given by
ng1 = n˜+
z21−α2
2ρ
, (5)
where ρ ≈ f/n˜. If ρ is a random quantity, it will be replaced by its expected value evaluated at n˜. Guenther [6] obtained
formula (5) for the one sample t test and two sample t test with equal variance (ρ = 1). The two sample t test with unequal
variances was studied by Schouten [7]. Schouten [7] indicated that formula (5) tends to underestimate the required size
for these simple t tests. For this reason, we also propose the following slightly more conservative estimate,
ng2 ≈ n˜+
z21−α2
2ρ
+
1
ng1
[
z21−α2
2ρ
]2
= ng1 +
1
ng1
[
z21−α2
2ρ
]2
. (6)
Equations (5) and (6) are proved in the appendix by using essentially the same argument as that of Schouten [7].
We will compare formulae (5) and (6) with the two step (TS) procedure described in Tang [5]. Let f(n˜) be the d.f.
when the total size is n˜. In the TS approach, the sample size is estimated as
n
TS
=
(tf(n˜),1−α2 + tf(n˜),P )
2V
(τ1 − τ0)2 . (7)
2.2. Sample size for some commonly used t tests
We illustrate how to use the generalized procedure in Section 2.1 to calculate the power and sample size for the one sample
t test, two sample t tests with or without equal variances, ANCOVA and MMRM. These tests are commonly used in the
analysis of randomized clinical trials.
2.2.1. One sample t test Suppose yi ∼ N(µ, σ2) for i = 1, . . . , n. Let τˆ = y¯ = n−1
∑n
i=1 yi and Vˆ = s
2 = (n−
1)−1
∑n
i=1(yi − y¯)2. The test statistic can be written as
T =
τˆ − τ0√
n−1Vˆ
=
√
n(y¯ − τ0)√
s2
.
The methods in Section 2 can be applied by setting τ1 = µ, V = σ
2, f = n− 1 and ρ ≈ 1. Note that Guenther [6] obtained
the noniterative sample size formula (5), and that formula (2) yields the exact power for the one-sample t test.
The methods for the one sample t test can be adapted for crossover trials without a period effect by setting τ1 as the
difference in two treatment means, and V = σ2d , where yit is the response for subject i in period t, and σ
2
d = var(yi1 − yi2).
Please refer to Section 3.3 for details.
2.2.2. Two sample t test with equal variances Suppose ygi ∼ N(µg, σ2) for i = 1, . . . , ng , g = 0, 1. Let n = n0 + n1
be the total size, and γg = ng/n the proportion of subjects in group g. Let y¯g = n
−1
g
∑ng
i=1 ygi, s
2 =
∑1
g=0
∑ng
i=1(ygi −
Statist. Med. 2015, 00 1–19 Copyright c© 2015 John Wiley & Sons, Ltd. www.sim.org 3
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y¯g)
2/(n− 2), τˆ = y¯1 − y¯0 and Vˆ = (γ−10 + γ−11 )s2. The test statistic is
T =
y¯1 − y¯0 − τ0√
(n−10 + n
−1
1 )s
2
=
√
n(y¯1 − y¯0 − τ0)√
(γ−10 + γ
−1
1 )s
2
.
The methods in Section 2 can be used by setting τ1 = µ1 − µ0, V = (γ−10 + γ−11 )σ2 = σ
2
γ0(1−γ0) , f = n− 2 and ρ ≈ 1.
Note that Guenther [6] obtained the noniterative sample size formula (5), and that Equation (2) gives the exact power.
The methods for the two sample t test can be adapted for crossover trials with a potential period effect, where τ1 is the
difference in two treatment means, γ0 is the proportion of subjects assigned to the one sequence, and V =
σ2d
4γ0(1−γ0) for
σ2d defined in Section 2.2.2. Please see Section 3.3 for details.
2.2.3. Two sample t test with unequal variances Suppose ygi ∼ N(µg, σ2g). Let y¯g = n−1g
∑ng
i=1 ygi, s
2
g =
∑ng
i=1(ygi −
y¯g)
2/(ng − 1), and τˆ = y¯1 − y¯0, Vˆ = s20/γ0 + s21/γ1. The t statistic is
T =
y¯1 − y¯0 − τ0√
n−10 s
2
0 + n
−1
1 s
2
1
=
√
n(y¯1 − y¯0 − τ0)√
γ−10 s
2
0 + γ
−1
1 s
2
1
.
The d.f. of the t test is computed using the Satterthwaite approximation
f =
2E2(n−10 s
2
0 + n
−1
1 s
2
1)
var(n−10 s
2
0 + n
−1
1 s
2
1)
=
(
σ20
n0
+
σ21
n1
)2
1
n0−1
(
σ20
n0
)2
+ 1n1−1
(
σ21
n1
)2 .
The unknown σ20 and σ
2
1 are replaced respectively by s
2
0 and s
2
1 in the data analysis.
The sample size methods in Section 2 can be applied by setting τ1 = µ1 − µ0, V = σ20/γ0 + σ21/γ1, and ρ = f/n ≈
V 2/(σ40/γ
3
0 + σ
4
1/γ
3
1). The sample size obtained by Schouten [7] is equivalent to Equation (5).
Formula (2) does not produce the exact power. The exact power can be calculated using the method of Moser et al [8].
2.2.4. Analysis of covariance (ANCOVA) Suppose in a clinical trial, ng subjects are randomized to treatment group g
(g = 1 for experimental, and 0 for placebo). The total sample size is n = n0 + n1. Let ygi be the response, and xgi the
q × 1 vector of covariates (excluding the treatment status and intercept) associated with subject i in group g. Let q∗ = q + 2
and γg = ng/n. The data can be analyzed by the ANCOVA
ygi ∼ N(µ+ τg + x′giβ, σ2), (8)
where µ is the intercept, τ is the treatment effect, β is the covariate effect, and σ2 is the residual variance in ygi that is
unexplained by the covariates and treatment.
The least square estimate of the treatment effect and its variance are given by
τˆ = ∆y −∆′xβˆ and var(τˆ ) = σ2Vx, (9)
where x¯g = n
−1
g
∑ng
i=1 xgi, y¯g = n
−1
g
∑ng
i=1 ygi, ∆y = y¯1 − y¯0, ∆x = x¯1 − x¯0, Sxx =
∑1
g=0
∑ng
i=1(xgi − x¯g)⊗2, Sxy =∑1
g=0
∑ng
i=1(xgi − x¯g)ygi, βˆ = S−1xx Sxy, Υ = nγ0γ1∆′xS−1xx∆x and Vx = n−10 + n−11 +∆′xS−1xx∆x = (1 + Υ)/(nγ0γ1).
Let f = n− q∗ and σˆ2 = f−1∑1g=0∑ngj=1[ygj − y¯g − (xgj − x¯g)′βˆ]2. In ANCOVA, the inference is made by assuming
xgi’s are known and fixed. Given xgi’s, the test statistic for H0 : τ = τ0 is distributed as
T =
τˆ − τ0√
σˆ2Vx
∼ t
[
f,
τ1 − τ0√
σ2Vx
]
and T 2 ∼ F
[
1, f,
(τ1 − τ0)2
σ2Vx
]
.
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At the design stage, xgi’s are typically unknown. The power is given by
P =
∫
Pr
[
F
(
1, f,
(τ1 − τ0)2
σ2Vx(Υ˜)
)
> t2f,1−α2
]
g(Υ˜)dΥ˜ ≈
∫
Pr
[
t
(
f,
√
(τ1 − τ0)2
σ2Vx(Υ˜)
)
> tf,1−α
2
]
g(Υ˜)dΥ˜, (10)
where g(Υ˜) is the probability density function (PDF) of Υ˜ = (n− 1− q)Υ/q, and Vx(Υ˜) = 1+qΥ˜/(n−q−1)nγ0γ1 . We assume
Υ˜ ∼ F (q, n− q − 1). The assumption holds exactly, and Equation (10) yields the exact power ifxgi is normally distributed
[5]. For nonnormal covariates, the power estimation based on the approximation Υ˜ ∼ F (q, n− q − 1) generally leads to
very accurate power estimate in randomized trials (i.e. no systematic difference in the distribution of xgi between two
groups), and this will be demonstrated in Section 4. To avoid numerical integration, we approximate Equation (10) by
replacing Υ˜ by E(Υ˜) ≈ (n− 1− q)/(n− 3− q)
P ≈ Pr
[
F
(
1, f,
nγ0γ1(τ1 − τ0)2
σ2(1 + qn−q−3 )
)
> t2f,1−α2
]
≈ Pr
[
t
(
f,
√
nγ0γ1(τ1 − τ0)2
σ2(1 + qn−q−3 )
)
> tf,1−α2
]
. (11)
In large trials, the sample size is commonly estimated based on the normal approximation and the asymptotic variance
var(τˆ ) ≈ σ2/(nγ0γ1)
nasy =
(z1−α2 + zP )
2σ2
γ0γ1(τ1 − τ0)2 . (12)
Another common approach is to invert the power formula below based on the t distribution and asymptotic variance [4],
P ≈ Pr
[
F
(
1, f,
nγ0γ1(τ1 − τ0)2
σ2
)
> t2f,1−α2
]
≈ Pr
[
t
(
f,
√
nγ0γ1(τ1 − τ0)2
σ2
)
> tf,1−α
2
]
, (13)
and it yields slightly better performance than Borm et al [9] approach, in which the total sample size from the normal
approximation (12) is inflated by 2 (i.e. 1 subject per arm).
The sample size based on the normal approximation and the exact variance is
n˜ =
(z1−α2 + zP )
2σ2 E(Vx)
(τ1 − τ0)2 = nasy
[
1 +
q
n˜− q − 3
]
, (14)
The solution to Equation (14) is given in the appendix, and it satisfies nasy + q < n˜ < nasy + q + 3. Inserting n˜ ≈
nasy + q + 1 into the last term in Equation (14) gives
n˜ ≈ nasy
[
1 +
q
nasy − 2
]
. (15)
Plugging n˜ into Equations (5) and (6) yields the size based on the t distribution (ρ = 1). We use the approximation (15)
instead of the explicit solution to Equation (14) to slightly simplify the calculation. It also enables the generalization of
the method to MMRM that will be investigated in Section 2.2.5.
In the two step approach, Equation (7) is calculated as
nu ≈ nuasy
[
1 +
q
nuasy − 2
]
,
where nuasy = (tn˜−q∗,1−α/2 + tn˜−q∗,P )
2σ2/[γ0γ1(τ1 − τ0)2].
2.2.5. Mixed effects model for repeated measures (MMRM) Suppose in a clinical trial, n subjects are randomly assigned
to the experimental (g = 1) or control (g = 0) treatment. Let ng and γg = ng/n be the number and proportion of subjects
Statist. Med. 2015, 00 1–19 Copyright c© 2015 John Wiley & Sons, Ltd. www.sim.org 5
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randomized to group g. Let ygi = (ygi1, . . . , ygip)
′ be the outcomes collected at p post-baseline visits, and xgi the q × 1
vector of covariates for subject i in group g. Let q∗ = q + 2. In clinical trials, the data are missing mainly due to dropout
[5]. At the design stage, it is reasonable to assume the missing data pattern is monotone in the sense that if ygij is observed,
then ygit’s are observed for all t ≤ j. Let ngj and πgj = ngj/ng be the number and proportion of subjects retained at visit
j in group g. The total number of subjects retained at visit j is mj =
∑1
g=0 ngj , and the pooled retention rate at visit j
is π¯j =
∑1
g=0 γgπgj . Without loss of generality, we sort the data so that within each group, subjects who stay in the trial
longer will have smaller index i than subjects who discontinue earlier.
The following MMRM is often used to analyze longitudinal clinical data collected at a fixed number of timepoints
[10, 11]
ygi ∼ Np[(µ1 +α′1xgi + τ1g, . . . , µp +α′pxgi + τpg)′,Σ]. (16)
where Σ is an unstructured (UN) covariance matrix. A structured covariance matrix (possibly induced via the use of
random effects) can be useful when individuals have a large number of observations, or varying time points of observations
[11]. In MMRM, inference is often made based on the restricted maximum likelihood (REML) and Kenward-Roger [12]
adjusted variance estimate to reduce the small sample bias [5].
Let Σ = LΛL′ be the LDL decomposition of Σ, where U =

1 0 . . . 0
−β21 1 . . . 0
. . . . . . 0
−βp1 . . . −βp,p−1 1
, L = U−1 and Λ =
diag(σ21 , . . . , σ
2
p). Let ljt be the (j, t)-th entry of L. Model (16) can be reorganized as the product of the following simple
regression models [13, 14]
ygij = z
′
gijθj + εgij for j ≤ p, (17)
where (µ
j
,α′j , τ j)
′ = (µj ,α′j , τj)
′ −∑j−1t=1 βjt(µt,α′t, τt)′, βj = (βj1, . . . , βj,j−1)′, θj = (µj ,α′j , τ j ,β′j)′,
zgij = (1,x
′
gi, g, ygi1, . . . , ygi,j−1)
′, and εgij
i.i.d.∼ N(0, σ2j ).
Tang [5] derives the REML estimate for model (17), and studies its theoretical properties
θˆj = (
1∑
g=0
ngj∑
i=1
zgijz
′
gij)
−1
1∑
g=0
ngj∑
i=1
zgijygij and σˆ
2
j =
∑1
g=0
∑ngj
i=1(ygij − z′gij θˆj)2
mj − q∗ .
The treatment effect estimate at visit p is τˆp =
∑p
j=1 lˆpj τˆ j , and its Kenword-Roger variance estimate is
v̂ar(τˆp) =
p∑
j=1
lˆ2pj σˆ
2
jVxj + 2
p∑
j=2
lˆ2pj σˆ
2
j
∑j−1
t=1 [Vxj − Vxt ]
mj − q∗ , (18)
where x¯gj = n
−1
gj
∑ngj
i=1 xgi, ∆j = x¯1j − x¯0j , Sxj =
∑1
g=0
∑ngj
i=1(xgi − x¯gj)⊗2, and Vxj = n−11j + n−10j +∆′jS−1xj ∆j .
We use slightly different notation in MMRM. We let τ1 denote the treatment effect at first timepoint. The true value for
τj underH1 is τj1, and its value underH0 is τj0. The test statistic for H0 : τp = τp0 vs H1 : τp = τp1,
T =
τˆp − τp0√
v̂ar(τˆp)
approximately follows a t distribution underH0, and the d.f. is obtained from the Satterthwaite approximation [12]
fˆ =
2Ê
2
(
∑p
j=1 lˆ
2
pj σˆ
2
jVxj )
v̂ar(
∑p
j=1 lˆ
2
pj σˆ
2
jVxj )
=
(
∑p
j=1 lˆ
2
pj σˆ
2
jVxj )
2
2
∑p
j=2 Aj +
∑p
j=1
lˆ2pja
2
j
mj−q∗
, (19)
where aj = lˆpj σˆ
2
jVxj , aj = (a1, . . . , aj−1)
′ and Aj = lˆ2pj σˆ
2
ja
′
jLˆ
′
j−1(Y
′
jQjYj)
−1Lˆj−1aj , Yj and Xj are mj × (j − 1)
6 www.sim.org Copyright c© 2015 John Wiley & Sons, Ltd. Statist. Med. 2015, 00 1–19
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and mj × q∗ matrices whose (n0jg + i)-th rows contain (ygi1, . . . , ygi,j−1) and (1,x′gi, g) respectively, and Qj = I −
Xj(X
′
jXj)
−1Xj . The derivation of Equation (19) and two other equations ((20) and (21)) below is given in the appendix.
Lu et al [2, 3] developed power and sample size methods for MMRM. These methods are based on the asymptotic
variance of τˆp instead of the commonly used Kenword-Roger adjusted variance estimate. The Kenword-Roger variance
estimate [12] provides a roughly unbiased estimate of the variance Vτ of τˆp while ignoring the lower order term
Vτ =
p∑
j=1
l2pjσ
2
jVxj +
p∑
j=2
l2pj
j−1∑
t=1
ωjtσ
2
t [Vxj − Vxt ]. (20)
where ωjt = σ
2
j /[(mj − q∗ − j)σ2t ] is the (t, t)-th element of L′j−1var(βˆj)Lj−1.
In the MMRM analysis, xgi’s are assumed to be fixed, but unknown at the design stage. In the power calculation, we
will replace Vxj ’s, fˆ and v̂ar(τˆp) by their expected values
V˜xj = E[Vxj ] =
̟pit
n
[1 +
q
nπ¯t − q − 3 ],
V ∗τ = E[v̂ar(τˆp)] =
p∑
j=1
cj V˜xj + 2
p∑
j=2
cj
∑j−1
t=1 (V˜xj − V˜xt)
mj − q∗ ,
f = E(fˆ) ≈ (
∑p
j=1 cj V˜xj )
2
2
∑p
j=2 cj
∑j−1
t=1 ctV˜
2
xt
mj−q∗−j +
∑p
j=1
c2j V˜
2
xj
mj−q∗
, (21)
where̟pit =
∑1
g=0(γgπgt)
−1 and cj = E(lˆ2pj σˆ
2
j ) = (1− j−1mj−q∗ )[l2pjσ2j +
∑p
k=j+1
1
mk−q∗−k l
2
pkσ
2
k]. It is possible to derive
a better approximation of the d.f. E(fˆ). We will not pursue it further here.
The power of the Wald test at a two-sided significance level of α is given by
P = Pr
[
F
(
1, f,
(τp1 − τp0)2
V ∗τ
)
> t2f,1−α2
]
≈ Pr
[
t
(
f,
|τp1 − τp0 |√
V ∗τ
)
≥ tf,1−α2
]
. (22)
One may approximate V ∗τ by Vτ , and/or f by fo = (m1 − q∗)ρo to simplify the calculation, where ρo =∑p
j=1 l
2
pjσ
2
j V˜x1/
∑p
j=1 l
2
pjσ
2
j V˜xj can be interpreted as the fraction of observed information among subjects retained at
visit 1. The following approximation of Tang [5] is only slightly less accurate than Equation (22) even in small samples
P = Pr
[
F
(
1, fo,
(τp1 − τp0)2
Vτ
)
> t2fo,1−α2
]
≈ Pr
[
t
(
f,
|τp1 − τp0 |√
Vτ
)
≥ tfo,1−α2
]
. (23)
The sample size based on the normal approximation and the asymptotic variance is given by
na =
(z1−α
2
+ zP )
2
∑p
j=1 l
2
pjσ
2
j̟pij
(τp1 − τp0)2
. (24)
The sample size based on the normal approximation and the variance defined in Equation (20) is given by
n˜ =
(z1−α2 + zP )
2Vτ
(τp1 − τp0)2
≈ na
p∑
j=1
bj
[
dj +
ej
naπ¯j − j + 1
]
. (25)
where bj = l
2
pjσ
2
j̟pij/
∑p
j=1 l
2
pjσ
2
j̟pij , dj = 1 + q/(naπ¯j − 2), and ej =
∑j
t=1(dj −̟pitdt/̟pij). To derive (25), we
assume nπ¯j − q − 1 ≈ naπ¯j by the same argument as that for Equation (15).
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Plugging n˜ and ρ = f/(n˜ π¯1 − q∗) into Equations (5) and (6) yields the size based on the t distribution, where f is
estimated using Equation (21) at n = n˜.
In the TS procedure, the sample size is calculated as
nu ≈ nua
p∑
j=1
bj
[
d∗j +
∑j
t=1(d
∗
j −̟pitd∗t /̟pij )
nua π¯j − (j − 1)
]
.
where nua = (tfl,1−α/2 + tfl,P )
2
∑p
j=1 l
2
pjσ
2
j̟pij/(τp1 − τp0)2, d∗j = 1+ q/(nua π¯j − 2), and fl = (n˜− q∗)ρ. It slightly
improves the TS procedure described in [5].
2.3. Numerical Examples
We present three numerical examples to assess the performance of the proposed methods in superiority trials.
Example 1 Table 1 displays the sample size estimates for the two sample t test using the exact method, normal
approximation, TS approach and the noniterative method. The variance is set to σ2 = 1 for the test assuming equal
variances, and (σ20 , σ
2
1) = (1, 4) in the test with unequal variances. Other parameters are set as γ0 = γ1 = 1/2, and
τ1 = µ1 − µ0 = 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25.
The sample size estimate is not rounded to an integer value for the purpose of comparison. The normal approximation
underestimates the sample size in all cases. The TS procedure produces slightly conservative size estimates particularly at
large µ1 − µ0. Although Equation (5) is more accurate than the normal approximation, it still underestimates the sample
size. The sample size estimate from Equation (6) is surprisingly close to the exact value in all cases.
In practice, the sample size must take an integer value. Equation (6) yields the same estimate (after rounding to integers)
as the exact method in all cases. Equation (5) underestimates the required size at µ1 − µ0 = 2.0 (simulated power based
on 1, 000, 000 trials is 79.05% at n = 10; exact power is 79.05%) and 1.5 (simulated power is 79.68% at n = 16; exact
power is 79.65%) for the tests with equal variances even after the sample size estimate is rounded up to the next integer.
We simulate 1, 000, 000 trials. The exact sample size per treatment arm is rounded up to the nearest integer. The
simulated power (SIM) is close to the nominal power in all cases. This is expected since there is more than 95% chance
that the simulated power (standard error ≤ 0.04%) lies within 0.08% of the true power.
Example 2 We assess the power and sample size formulae for ANCOVA based on two models. In Model 1, the baseline
outcome xgi ∼ N(0, 1) is used as the covariate (q = 1), and ygi ∼ N(0.5 + τg + 0.5xgi, σ2), where γ0 = γ1 = 1/2,
σ2 = 1 and τ = 1, 1.25, 1.5, 1.75, 2.
In Model 2, the covariates (q = 3) include the baseline outcome xgi, and a categorical prognostic factor A with three
levels, and ygi ∼ N(ηs + τg + 0.5xgi, σ2) for subjects in level s of A, where η1 = 0.5, η2 = 0, η3 = 1. Subjects are in
level 1, 2, and 3 of factor A with probability 0.4, 0.4, and 0.2 respectively. Other setup is the same as Model 1. The power
and sample size depend on (τ, σ2, γ0, γ1, q). Other parameters are specified for data simulation.
Table 2 reports the results. The sample size per arm is calculated by numerical inversion of Formula (10) at the 80%
power, and rounded up to the nearest integer. We simulate 1, 000, 000 trials. For Model 1 with normally distributed
covariates, Formula (10) yields the exact power estimate. It also produces very accurate power estimate for Model 2
with nonnormal covariates, which are within 0.1% of the simulated power in all cases. Formula (11) is generally accurate.
Its performance slightly deteriorates when the number of covariates is relatively large in small samples. In the worst case
(q = 3, n0 = n1 = 7 subjects per arm), the estimate by Equation (11) deviates from the simulated power by 0.59%.
We compare several sample size methods. The normal approximation can substantially underestimate the sample size.
For example, when τ = 2 in Model 2, the target size is 13.66while Equations (12) and (15) yield the estimates of 7.85 and
11.87 respectively. As a rule of thumb, the sample size will be underestimated by about q + z21−α/2/2 by Equation (12),
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Table 1: Sample size needed to achieve 80% power at the two-sided significance level of α = 0.05 for the two sample t tests:
(a) The sample size estimate is not rounded to the nearest integer for the purpose of comparison;
(b) The exact power and sample size are calculated by using Equation (3) for tests with equal variances, and by Moser et al
[8] method for the tests with unequal variances;
(c) The exact size per arm is rounded up to the nearest integer;
(d) Simulated power (SIM) based on 1, 000, 000 simulated trials.
estimated total size(a) at α = 0.05, P = 80%
two noniterative power (%)
µ1 − µ0 exact(b) normal step (5) (6) size(c) exact(b) SIM(d)
two sample t test with equal variances
0.50 127.53 125.58 127.59 127.50 127.53 64 80.15 80.18
0.75 57.80 55.81 57.90 57.73 57.80 29 80.14 80.16
1.00 33.43 31.40 33.59 33.32 33.43 17 80.70 80.75
1.25 22.19 20.09 22.46 22.01 22.18 12 83.30 83.30
1.50 16.12 13.95 16.56 15.87 16.11 9 84.76 84.76
1.75 12.50 10.25 13.22 12.17 12.48 7 85.16 85.12
2.00 10.18 7.85 11.36 9.77 10.15 6 87.64 87.64
2.25 8.62 6.20 10.59 8.12 8.58 5 87.46 87.49
two sample t test with unequal variances
0.50 316.59 313.96 316.64 316.57 316.59 159 80.18 80.13
0.75 142.19 139.54 142.27 142.15 142.20 72 80.50 80.52
1.00 81.18 78.49 81.29 81.10 81.19 41 80.40 80.42
1.25 52.97 50.23 53.12 52.85 52.97 27 80.79 80.84
1.50 37.68 34.88 37.89 37.50 37.68 19 80.36 80.36
1.75 28.49 25.63 28.79 28.24 28.48 15 82.21 82.17
2.00 22.55 19.62 22.97 22.23 22.54 12 82.74 82.72
2.25 18.51 15.50 19.10 18.12 18.49 10 83.52 83.47
and by about z21−α/2/2 by Equation (15). The method by inverting Equation (13) underestimates the size by about q in all
cases. Formulae (5) and (6) and the TS procedure generally yield accurate size estimates. The estimate from Equation (6)
tends to be the closest to the exact size except when the number of covariates is large and the total sample size is small.
Example 3 We revisit the sample size estimation based onMMRM in the design of a new antidepressant trial investigated
by Tang [5]. The primary objective of the trial is to assess the effect of a new compound on depression. The Hamilton
17-item rating scale for depression (HAMD17) will be collected at baseline and p = 4 post-randomization visits. Suppose
ygi1
ygi2
ygi3
ygi4
 ∼ N


µgi1
µgi2
µgi3
µgi4
 ,

19.68 16.45 15.39 16.36
16.45 34 25.34 26.13
15.39 25.34 38.44 33.91
16.36 26.13 33.91 45.28

 ,
and the retention rate is (π01, . . . , π04) = (1, 0.92, 0.86, 0.74) and (π11, . . . , π14) = (1, 0.93, 0.87, 0.76), where µgi1 =
3.3 + 0.72ygi0 + 0.1g, µgi2 = 2.7 + 0.69ygi0 − 1.5g, µgi3 = 2.9 + 0.61ygi0 − 2.3g, µgi4 = 1 + 0.67ygi0 + τ4 g. These
parameters are specified based roughly on the MMRM analysis of an antidepressant trial. The sample size depends on
(τ4,Σ, π
′
gjs, q). Other parameters are specified in order to simulate the data.
We set τ4 = −4, −8 or −12. Three alternative covariance structures are considered to serve as the sensitivity analysis:
1) a compound symmetry (CS) structure: Σkk = 45 and Σkj = 15 if k 6= j; 2) an autoregressive (AR(1)) structure
Σjk = 45× 0.8|j−k|; 3) a Toeplitz (TO) structure Σjk = 40− 6|j − k|.
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Table 2: Calculated sample sizes and power estimates for ANCOVA:
(a) The estimate is exact for normally distributed covariates (i.e. q = 1). The per arm size is rounded up to the nearest integer;
(b) Simulated power (SIM) based on 1, 000, 000 simulated trials.
estimated total size at P = 80%, α = 0.05 size power (%)
inversion normal inversion two noniterative per nominal
τ (10)(a) (12) (15) (13) step (5) (6) arm (a) SIM(b) (10) (11)
q = 1 : ygj ∼ N(µ+ τg + 0.5xgj , 1)
1.00 34.50 31.40 32.46 33.50 34.65 34.38 34.49 18 81.85 81.80 81.79
1.25 23.30 20.09 21.20 22.30 23.54 23.12 23.28 12 81.34 81.34 81.30
1.50 17.26 13.95 15.12 16.28 17.66 17.04 17.26 9 81.96 82.00 81.93
1.75 13.67 10.25 11.49 12.72 14.30 13.41 13.69 7 81.20 81.25 81.07
2.00 11.37 7.85 9.19 10.47 12.32 11.11 11.44 6 82.92 82.96 82.74
q = 3 : ygj ∼ N(ηs + τg + 0.5xgj , 1) category s = 1, 2, 3
1.00 36.64 31.40 34.60 33.64 36.77 36.52 36.62 19 81.72 81.64 81.61
1.25 25.49 20.09 23.42 22.54 25.71 25.35 25.49 13 80.99 80.98 80.88
1.50 19.49 13.95 17.46 16.66 19.86 19.38 19.57 10 81.40 81.38 81.18
1.75 15.93 10.25 13.98 13.26 16.48 15.90 16.13 8 80.18 80.25 79.78
2.00 13.66 7.85 11.87 11.19 14.39 13.80 14.06 7 81.59 81.61 81.00
We calculate the total size needed to achieve 90% power at α = 0.05 using Equation (6), which is rounded up to
the nearest integer. The size estimates from the normal approximation (i.e. Equations (24), (25)), the TS procedure and
Formula (5) are reported for comparisons. In each case, 40, 000 datasets are simulated and analyzed using MMRM (q = 1)
with xgi = ygi0. There is about 95% chance that the simulated power lies within 0.3% of the true power.
We repeat the above process for a more complex MMRM. The setup is similar except that the covariates include the
baseline outcome ygi0 and a categorical prognostic factor A with three levels. We assume that
ygi ∼ N([ηs + µgi1, ηs + µgi2, ηs + µgi3, ηs + µgi4]′,Σ)
for subjects in category s, where η1 = 0, η2 = −0.5, η3 = 0.5. Each subject is in level 1, 2 and 3 of the prognostic
factor A with probability 0.3, 0.4, and 0.3 respectively. The simulated data are analyzed using MMRM (q = 3) with
xi = (ygi0, Agi1, Agi2)
′, where Agik = 1 if subject i in group g is in category k, and 0 otherwise. The effect of factor A is
assumed to vary across visits in the analysis, but be constant over time in simulating the data.
The result is summarized in Table 3. The sample size is underestimated by the normal approximation. The TS procedure
and Formula (6) give similar sample size estimates. Formula (22) yields power estimates that are within 0.5% of the
simulated power in nearly all cases. The power equation (23) is slightly less accurate than Equation (22) primarily when
τ4 = −12. In the worst case, the estimate by Equation (23) deviates from the simulated power by about 1.5%.
3. Power and sample size for NI, equivalence and bioequivalence trials
The methods described in Section 2 can be easily adapted for NI, equivalence and BE trials. In these trials, inference
is made based on the confidence interval (CI) approach. Suppose the CI for the treatment effect τ is [cl, cu] = [τˆ −
tf,1−α/2
√
Vˆ , τˆ + tf,1−α/2
√
Vˆ ].
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Table 3: Calculated sample sizes and power estimates for testing τ4 = 0 in MMRM:
(a) Sample size estimates are not rounded to integer values for the purpose of comparison;
(b) Sample size in simulation is estimated using (6), and rounded up to the nearest integer. The difference
in sample size between two arms is ≤ 1;
(c) Simulated power (SIM) based on 40, 000 simulated trials.
estimated total size at P = 90%, α = 0.05 (a) total power (%)
inversion normal two noniterative size nominal
τ41 (22) (24) (25) step (5) (6) n
(b) SIM(c) (22) (23)
covariates (q = 1): baseline HAMD17
UN −12 20.31 15.24 17.16 20.85 20.03 20.44 21 91.33 91.32 92.36
−8 38.52 34.28 35.95 38.63 38.31 38.45 39 90.15 90.40 90.57
−4 140.88 137.12 138.67 140.95 140.83 140.86 141 89.92 90.02 90.02
CS −12 22.48 16.77 19.29 22.78 22.22 22.60 23 90.37 90.92 91.78
−8 42.63 37.73 39.88 42.69 42.41 42.56 43 89.89 90.28 90.41
−4 155.37 150.90 152.89 155.44 155.31 155.34 156 90.15 90.12 90.12
AR −12 20.53 15.34 17.34 21.06 20.25 20.67 21 90.89 90.92 92.05
−8 38.85 34.52 36.24 38.95 38.63 38.78 39 89.87 90.12 90.30
−4 141.91 138.07 139.67 141.98 141.85 141.89 142 90.18 90.02 90.01
TOEP −12 18.52 13.34 15.28 19.30 18.28 18.77 19 91.41 91.09 92.48
−8 34.28 30.02 31.66 34.41 34.04 34.21 35 90.65 90.68 90.90
−4 123.80 120.08 121.59 123.87 123.74 123.77 124 90.00 90.05 90.04
covariates (q = 3): baseline HAMD17, a categorical factor with three levels
UN −12 22.97 15.24 20.11 23.38 22.98 23.33 24 91.56 91.91 92.79
−8 41.07 34.28 38.52 41.14 40.89 41.03 42 90.56 90.76 90.92
−4 143.28 137.12 141.06 143.34 143.22 143.25 144 89.99 90.15 90.14
CS −12 25.38 16.77 22.65 25.66 25.57 25.91 26 90.19 91.09 91.83
−8 45.44 37.73 42.75 45.50 45.30 45.45 46 89.93 90.42 90.55
−4 158.01 150.90 155.53 158.08 157.96 157.99 158 89.99 90.00 90.00
AR −12 23.22 15.34 20.35 23.62 23.25 23.61 24 91.13 91.48 92.43
−8 41.44 34.52 38.85 41.51 41.26 41.40 42 90.21 90.46 90.64
−4 144.35 138.07 142.09 144.40 144.28 144.31 145 89.93 90.13 90.13
TOEP −12 21.17 13.34 18.29 21.71 21.27 21.69 22 91.59 91.82 92.97
−8 36.83 30.02 34.24 36.92 36.63 36.79 37 90.23 90.17 90.41
−4 126.19 120.08 123.96 126.24 126.11 126.15 127 90.03 90.19 90.19
3.1. Noninferiority trials
In a NI trial, the objective is to demonstrate that the test product is not clinically inferior to a standard treatment, or
equivalently that the test treatment is not worse than the active control by a prespecified small amountM0 called margin
[15, 16, 17, 18]. The NI trial can be used if it would be unethical to run a placebo controlled trial or because the new
treatment may offer important advantages over the standard treatment in terms of convenience of administration, improved
safety, reduced cost, or better compliance [17, 18]. If a lower score indicates better health status, then M0 > 0, and the
noninferiority can be claimed when the CI for τ lies belowM0 (i.e. cu < M0). If a higher score indicates better response,
noninferiority is demonstrated if the CI for τ lies above M0 < 0 (i.e. cl > M0). The power and sample size formulae in
Section 2 can be used by simply setting [18] τ0 =M0. The NI test is one tailed, and the actual type I error is α/2.
3.2. Equivalence trials
An equivalence trial aims to show that the test product is neither superior nor inferior to the reference product, and
is particularly useful in the development of biosimilar products [19]. The two treatments are not clinically different if
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the whole CI for τ lies completely within [Ml,Mu], where Ml < 0 and Mu > 0 are the pre-specified lower and upper
equivalence margins. As shown in the appendix, a generalized power formula for the equivalence test can be obtained by
extending Phillips [20, 21] approach for two sample t tests (the true effect τ1 must lie in [Ml,Mu])
P =
∫ n(Mu−Ml)2
4V t2
f,1−α/2
0
[
Φ
(
Mu − τ1√
n−1V
− tf,1−α2
√
ξ
)
− Φ
(
Ml − τ1√
n−1V
+ tf,1−α2
√
ξ
)]
g(ξ)dξ, (26)
where g(ξ) is the PDF of ξ = VˆV ∼
χ2f
f . A simpler formula [1, 22] that does not require numerical integration has been
developed to approximate the equivalence power
P = 1− Pr
[
t(f,
Mu − τ1√
n−1V
) < tf,1−α2
]
− Pr
[
t(f,
τ1 −Ml√
n−1V
) < tf,1−α2
]
. (27)
Equation (27) works very well when n is large or when the estimated power is large. However, it underestimates the power,
or even yields negative estimate if the sample size is too small. The explanation is given in the Appendix.
Formula (26) is exact for the one sample t test and two sample t test with equal variance. Exact power formulae for the
two sample t test with unequal variance and ANCOVA with normally distributed covariates are derived in the Appendix.
WhenMu − τ1 = τ1 −Ml, the sample size formulae in Section 2 can be adapted for the equivalence trial by replacing
(z1−α/2 + zp)2 and τ1 − τ0 respectively by (z1−α/2 + z(1+P )/2)2 and (Mu −Ml)/2. In general, there is no closed form
sample size solution in the equivalence trial. Let∆min = min{Mu − τ1, τ1 −Ml} and∆max = max{Mu − τ1, τ1 −Ml}.
By the same argument as Tang [18], we derive the following sample size bounds based on Equation (5)
ng1l =
[z1−α/2 + z(1+P )/2]2 V
∆2max
+
z21−α2
2ρ
≤ n ≤ ng1u =
[z1−α/2 + z(1+P )/2]2 V
∆2min
+
z21−α2
2ρ
.
Similar sample size bounds can be obtained on basis of Equation (6).
3.3. Bioequivalence trials
The purpose of the trial is to assess the BE in drug absorption between drug products [23, 24], and it is useful in the
development of generic drug products or new formulations of an existing product. The statistical principles underlying
the BE and equivalence trials are the same. In the BE trial, the PK parameters such as Cmax (maximum concentration)
and AUC (area under the concentration time curve) are used as the primary endpoints, which are approximately log-
normally distributed, and generally log-transformed in the analysis [23]. Let µ∗A and µ
∗
B be the mean of the log-transformed
PK parameter for product A and B respectively. The means of untransformed PK parameters are µA = exp(µ
∗
A) and
µB = exp(µ
∗
B). The BE between two products can be claimed [23, 24] if the 90% CI for µB/µA is entirely within the BE
limits of (80%, 125%), or equivalently if the 90% CI for µ∗B − µ∗A lies completely within [−0.2231, 0.2231].
For drug products with relatively long half-lives, a parallel design may be used [23]. The power and sample size
formulae for the two sample t test with or without equal variances can be used directly by setting τ1 = µ
∗
B − µ∗A,
Ml = −0.2231,Mu = 0.2231, α = 0.1, and σ2 (or σ21 , σ22) to be the variance of log(AUC) or log(Cmax).
A crossover design is generally preferred to reduce the sample size whenever feasible. The methods for the one
sample and two sample t tests may be adapted for the crossover trial. For simplicity, we assume all subjects complete
the study in the sample size calculation, and the estimated sample size may then be adjusted for the dropout. Let
ng be the number of subjects randomized to sequence g (g = 1 for A/B, 0 for B/A) in a two period, two treatment
crossover trial. Suppose the washout period is long enough so that the carryover effect is eliminated. Let Pgik denote
the PK parameter [e.g. log(AUC)] for subject i, period k, sequence g. Let d1i = P1i2 − P1i1 for subjects in sequence
A/B, and d0i = P0i1 − P0i2 for sequence B/A. If there is no period effect, then dgi ∼ N(µ∗B − µ∗A, σ2d) for all subjects.
The 90% CI for µ∗B − µ∗A is [d¯.. − tn−1,0.95
√
σˆ2
d
n , d¯.. + tn−1,0.95
√
σˆ2
d
n ], where n = n0 + n1, d¯.. =
∑1
g=0
∑ng
i=1 dgi/n, and
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σˆ2d =
∑1
g=0
∑ni
i=1(dgi − d¯..)2/(n− 1). The methods for the one sample t test (described in Section 3.2) can be used by
setting τ1 = µ
∗
B − µ∗A, V = σ2d , f = n− 1, ρ ≈ 1,Ml = −0.2231,Mu = 0.2231 and α = 0.1.
If there is a possible period effect (denoted by δ) in the crossover study, then d1i ∼ N(µ∗B − µ∗A − δ, σ2d), d0i ∼ N(µ∗B −
µ∗A + δ, σ
2
d). An unbiased estimate [22] of µ
∗
B − µ∗A is (d¯1 + d¯0)/2, and the 90%CI is [ d¯1+d¯02 − tn−2,0.95
√
nσˆ2d
4n0n1
, d¯1+d¯02 +
tn−2,0.95
√
nσˆ2d
4n0n1
], where d¯g =
∑ng
i=1 dgi/ng, and σˆ
2
d =
∑1
g=0
∑ni
i=1(dgi − d¯g)2/(n− 2). The power and sample size
methods for the two sample t test with equal variance (described in Section 3.2) can be adapted by setting τ1 = µ
∗
B − µ∗A,
γg = ng/n, σ
2 = σ2d/4 [i.e. V = σ
2
d/(4γ0γ1)], f = n− 2, ρ ≈ 1,Ml = −0.2231,Mu = 0.2231 and α = 0.1.
In equivalence and BE trials, the inference can be equivalently made based on the two one-sided test (TOST) procedure
[25, 20], and the actual type I error is α/2.
3.4. Numerical examples
Example 4 A simulation study is conducted to assess the power and sample size methods for a BE crossover trial. We set
µ∗A = µ
∗
B , σ
2 = σ2d/4 = 0.0125k for k = 1, . . . , 6. The analysis method is described in the last paragraph in Section 3.3.
There is no period effect (δ = 0) in the data simulation, but the analysis accounts for a potential period effect.
The result is reported in Table 4. The two noniterative formulae yield the sample size estimates that are the closest to
the exact value. Formulae (26) gives the exact power estimate. At the target size, formulae (27) yields very accurate power
approximation. However its performance deteriorates when we reduce the required sample size by half, and the estimated
power deviates from the simulated power by about 9% at σ2 = σ2d/4 = 0.0125 and n0 = n1 = 3.
Since there is no period effect, the data can also be analyzed by the one sample t test described in Section 3.3. The
variance
σ2d
n of µˆ
∗
B − µˆ∗A in the one sample t test is identical to that nσˆ
2
d
4n0n1
=
σ2d
n in the two sample t test when n0 = n1
although the d.f. in the one sample t test is n− 1 instead of n− 2. The use of the one sample t test leads to only a minor
improvement in the power, and the power estimate is presented in footnote (f) of Table 4.
Table 4: Calculated sample sizes and power estimates for tesing BE in a crossover trial using the two sample t test:
(a) Estimated using the formulae in Sections 2, where α = 0.1 and P is modified as (1 + 80%)/2 = 0.9 (see Section 3.2).
The sample size estimates are not rounded to the nearest integer for the purpose of comparison;
(b) The exact sample size are calculated by inverting Equation (26);
(c) The per sequence sample size is rounded to the nearest integer;
(d) The per sequence sample size is reduced by half in order to assess the power formula (27);
(e) Simulated power (SIM) based on 1, 000, 000 simulated trials.
(f) The exact power for the one sample t test is 79.31%, 78.00%, 81.52%, 80.30%, 79.53%, 80.99% in the six cases.
estimated total size(a) at α = 0.1, P = 80%
two noniterative power (%) power (%)
σ2 = σ2d/4 exact
(b) normal step (5) (6) size(c) SIM(e) (26)(f) (27) size(d) SIM(e) (26) (27)
0.0125 10.29 8.60 11.17 9.95 10.14 5 78.13 78.14 78.10 3 37.88 37.94 28.74
0.0250 18.72 17.20 19.19 18.55 18.65 9 77.73 77.71 77.71 5 34.15 34.18 30.56
0.0375 27.27 25.80 27.65 27.15 27.22 14 81.38 81.42 81.42 7 32.11 32.14 30.13
0.0500 35.84 34.40 36.19 35.75 35.80 18 80.21 80.24 80.24 9 30.94 30.95 29.70
0.0625 44.42 43.00 44.75 44.35 44.39 22 79.53 79.49 79.49 12 36.67 36.70 36.41
0.0750 53.01 51.60 53.33 52.95 52.98 27 81.06 80.97 80.97 14 35.23 35.25 35.04
Example 5 We assess the proposed methods for testing equivalence using the two sample t test with unequal variances.
We set τ1 = 0, σ
2
0 = 1, σ
2
1 = 4, and γ0 = γ1 = 1/2. For illustrative purposes, we use the marginMu = −Ml = 0.5, 1.0 or
1.5. Please refer to the regulatory guidelines [15, 19, 16] on the specification of the NI and equivalence margins.
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We estimate the sample size needed to achieve 80% power at α = 0.05. The two noniterative sample size estimates are
very close to the exact size obtained by numerically inverting the power equation (31). We assess the power formulae at
two sample sizes. The exact power by Formula (31) is within 0.08% of the simulated power in all cases. At the target size,
both formulae (32) and (27) yield very good power approximations, and are muchmore accurate than Equation (26). When
we reduce the sample size by half, formulae(32) and (27) underestimate the power particularly atMu = −Ml = 1.5.
Table 5: Calculated sample sizes and power estimates for tesing equivalence using two sample t tests with unequal variance:
(a) Estimated using the formulae in Sections 2, where α = 0.05 and P is modified as (1 + 80%)/2 = 0.9 (see Section 3.2).
(b) The exact sample size are calculated by inverting Equation (31);
(c) The per treatment sample size is rounded to the nearest integer;
(d) The per treatment sample size is reduced by half in order to assess the approximate power formulae;
(e) Simulated power (SIM) based on 1, 000, 000 simulated trials.
total size(a) at P = 0.8, α = 0.05
two noniterative power (%) power (%)
Mu exact
(b) normal step (5) (6) size(c) SIM(e) (31) (32) (26) (27) size(d) SIM(e) (31) (32) (26) (27)
0.5 422.9 420.3 423.0 422.9 422.9 211 79.88 79.87 79.87 79.40 79.87 106 25.77 25.70 25.70 25.75 25.70
1.0 107.8 105.1 107.9 107.7 107.7 54 80.13 80.13 80.13 78.27 80.14 27 24.77 24.83 23.94 27.74 23.98
1.5 49.47 46.70 49.66 49.31 49.45 25 80.64 80.64 80.64 76.79 80.69 12 22.65 22.63 17.56 29.05 17.78
Example 6 We assess the sample size and power determination methods for testing equivalence based on MMRM. The
simulation setup is similar to that in Example 3 except that the true effect is τ11 = τ21 = τ31 = τ41 = 0. The margins
satisfyMu = −Ml = 4 or 8. SinceMu − τ41 = τ41 −Ml, the noniterative sample size procedure is applicable.
The power is calculated by adapting the power equation (22) as
P = 1− Pr
[
t
(
f,
Mu − τp1√
V ∗τ
)
< tf,1−α
2
]
− Pr
[
t
(
f,
τp1 −Ml√
V ∗τ
)
< tf,1−α
2
]
. (28)
Table 6 summarizes the results, and the performance is comparable to that for superiority tests reported in Example 3.
Simulation also demonstrates the accuracy of the power and sample size formulae for ANCOVA in equivalence trials.
The results are not reported due to limited space. Sample SAS codes for the power and sample size determinations for t
tests, ANCOVA and MMRM in superiority, NI and equivalence trials are provided in the Supporting Information.
4. Discussion
We develop a generalized sample size procedure for t tests by modifying and extending Guenther’s method for the one
sample and two sample t tests. The procedure is simple and noniterative by adding a few correction terms to the sample size
from the normal approximation. Numerical examples demonstrate its excellent performance. Both formulae (5) and (6)
slightly outperform the TS procedure, and are muchmore accurate than the approaches based on the normal approximation
or the asymptotic variance in small and moderate samples.
Formula (6) tends to be slightly more accurate than formula (5) for the one-sample and two sample t tests. In ANCOVA
and MMRM, the noniterative procedure (particularly formula (6)) has a tendency to slightly overestimate the required size
if the number of covariates is relatively large, and the total size is small (possibly because of the approximation method
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Table 6: Calculated sample sizes and power estimates for testing equivalence at visit p in MMRM:
(a) Sample size estimates are not rounded to integer values for the purpose of comparison;
(b) Sample size in simulation is estimated via (6) [P is modified as (1 + 90%)/2 = 0.95], and rounded up
to the nearest integer. The difference in sample size between two arms is ≤ 1;
(c) Simulated power (SIM) based on 40, 000 simulated trials.
estimated total size at P = 90%, α = 0.05 (a) total
Margin inversion normal two noniterative size power (%)
Mu = −Ml (28) (24) (25) step (5) (6) n (b) SIM(c) (28)
covariates (q = 1): baseline HAMD17
UN 8 46.52 42.40 44.03 46.83 46.33 46.45 47 90.60 90.42
4 173.32 169.58 171.12 173.58 173.27 173.29 174 90.22 90.15
CS 8 51.45 46.66 48.77 51.75 51.26 51.38 52 89.83 90.43
4 191.06 186.62 188.60 191.36 191.01 191.04 192 90.05 90.19
AR 8 46.90 42.69 44.38 47.21 46.71 46.83 47 90.19 90.09
4 174.57 170.75 172.34 174.84 174.52 174.55 175 89.99 90.09
TOEP 8 41.25 37.13 38.73 41.58 41.05 41.18 42 90.66 90.73
4 152.20 148.51 150.01 152.46 152.14 152.17 153 90.26 90.20
covariates (q = 3): baseline HAMD17, a categorical factor with three levels
UN 8 49.04 42.40 46.55 49.31 48.86 48.97 49 89.57 89.97
4 175.70 169.58 173.50 175.96 175.65 175.68 176 89.97 90.06
CS 8 54.22 46.66 51.57 54.52 54.09 54.20 55 89.68 90.61
4 193.70 186.62 191.23 193.99 193.65 193.68 194 89.81 90.06
AR 8 49.46 42.69 46.94 49.73 49.28 49.39 50 90.14 90.47
4 176.99 170.75 174.76 177.25 176.93 176.96 177 89.76 90.00
TOEP 8 43.77 37.13 41.25 44.06 43.58 43.70 44 90.06 90.24
4 154.57 148.51 152.37 154.82 154.51 154.54 155 90.00 90.11
used to handle the covariates). However, these scenarios rarely happen in practice. Let’s take the last case in Table 2 as
an example. In this case, q = 3, n ≈ 14, and the total number of model parameters is 6. If the model includes too many
covariates, the power may actually reduce, and the parameter estimate may not be consistent [26]. The regulatory guideline
[27] recommends that the primary analysis shall include only a few important covariates.
Since the final sample size takes only integer values, the estimate from the noniterative procedure after rounding is
generally exact or nearly exact (deviate from the target sample size by at most 1 in our examples). It would be beneficial
to evaluate the power at several integer sample sizes near the noniterative estimate in order to find the most appropriate
sample size. It is a common practice to round the total sample size or the size per treatment arm up to the next integer, and
it ensures that the actual power is at least as large as the target power. A smaller sample size may also be used sometimes.
For example, in case 5 (µ1 − µ0 = 1.5 and the exact size is 16.12) in Table 1, we may round the total sample size down to
n = 16 if it is extremely difficult to enroll patients (e.g. in rare disease trials) since the exact power 79.65% at n = 16 is
almost close to the target 80% power.
An extensive literature [28, 29, 5] indicates that the t tests, ANCOVA and MMRM are fairly robust to deviations from
non-normality. As confirmed by unreported simulation studies (see also Tang [5]), the proposed sample size procedure
works well for mild to moderate nonnormal data. It is always recommended to verify the power and sample size estimate
by simulations particularly when the data are non-normal or the sample size is small. We have focused on the unstratified
trials. In a companion paper, we will investigate the power and sample size determination for testing the main treatment
effect and treatment × stratum interaction in stratified trials using ANCOVA [30].
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Appendix: Technical Proofs
Proof of equations (5) and (6): The type I error and power are calculated by assuming that Z1 = [
√
n(τˆ − τ) − c(
√
Vˆ −√
V )]/σz ∼ N(0, 1) and Z2 = [
√
n(τˆ − τ) + c(
√
Vˆ −√V )]/σz ∼ N(0, 1), where c = tf,1−α/2, σ2z = V [1 + c2/(2f)],
τ = τ0 underH0, and τ = τ1 under H1. The type I error of the test (τ = τ0 underH0) is
Pr(|T | > tf,1−α2 ) = Pr
[
Z1 > c
√
V
σ2z
]
+ Pr
[
Z2 < −c
√
V
σ2z
]
= 2Φ
[
−c
√
V
σ2z
]
.
Setting the type I error at α yields an approximation of the critical value c = tf,1−α/2
c
√
V
σ2z
= z1−α2 and c = z1−α2
√
2f
2f − z21−α2
.
The power (τ = τ1 underH1) is approximately
P = Pr(|T | > tf,1−α
2
) = Φ
[
−Z1 < τ1 − τ0√
n−1σ2z
− c
√
V
σ2z
]
+Φ
[
Z2 <
τ0 − τ1√
n−1σ2z
− c
√
V
σ2z
]
≈ Φ
[
|τ1 − τ0|√
n−1σ2z
− z1−α
2
]
.
Inverting the above power formula yields the sample size
ng1 =
(z1−α2 + zP )
2 σ2z
(τ1 − τ0)2 ≈ n˜+ hf
z21−α2
2ρ
,
where ρ = f/n ≈ f/n˜ and hf = 2f/(2f − z21−α/2). Equations (5) and (6) are obtained respectively by approximating
hf ≈ 1, and hf ≈ 1 + z21−α/2/(2ng1ρ).
Solution of Equation (14): Equation (14) can be reorganized as n˜2 − n˜(nasy + q + 3) + 3nasy = 0. Its solution is
n˜ =
(nasy + q + 3) +
√
(nasy + q + 3)2 − 12nasy
2
.
A little algebra shows that nasy + q − 3 <
√
(nasy + q + 3)2 − 12nasy < nasy + q + 3 by noting that q > 0 is a positive
integer. Thus nasy + q < n˜ < nasy + q + 3.
Proof of Equation (19): By Tang [5], we have v̂ar(βˆj) = σˆ
2
j (Y
′
jQjYj)
−1, v̂ar(σˆ2j ) = 2σˆ
4
j /(mj − q∗),
∂lpj/∂βk = lpk(l1j , . . . , lk−1,j)′ [it is 0 if j ≥ k]. Thus ∂(
∑p
j=1 lˆ
2
pj σˆ
2
jVxj )/∂βk = 2lpkakL
′
k−1. Also βˆj’s and σˆ
2
j ’s are
independent. Equation (19) holds since by delta method, we have
v̂ar(
p∑
j=1
lˆ2pj σˆ
2
jVxj ) = 4
p∑
j=2
Aj + 2
p∑
j=1
lˆ2pja
2
j
mj − q∗ .
Derivation of ωjt’s in Equation (20): The variance of βˆ is given by
var(βˆj) = σ
2
jE[(Y
′
jQjYj)
−1] =
σ2j
mj − q∗ − jΣ
−1
j−1
since Y ′jQjYj follows a Wishart distribution withmj − q∗ d.f. and scale matrix Σj−1, where Σj−1 is the leading
(j − 1)× (j − 1) submatrix of Σ. Thus L′j−1var(βˆj)Lj−1 is a diagnoal matrix, and its (t, t) entry is given by
ωjt = σ
2
j /[(mj − q∗ − j)σ2t ].
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Derivation of cj’s in Equation (21): By Tang [5], E(lˆ
2
pj)σ
2
j = l
2
pjσ
2
j + var(lˆpj)σ
2
j = l
2
pjσ
2
j +
∑p
k=j+1 l
2
pkωkjσ
2
j , and
cj = E(lˆ
2
pj σˆ
2
j ) = (1− j−1mj−q∗ )E(lˆ2pj)σ2j , where ωkjσ2j = σ2k/(mk − q∗ − k).
Proof of Equations (26) and (27): Let ξ = VˆV . Then fξ ∼ χ2f . Conditioning on Vˆ , the equivalence power is given by
ϕ(ξ) = Pr(cl > Ml, cu < Mu|Vˆ ) = Φ(Mu − τ1√
n−1V
− tf,1−α
2
√
ξ)− Φ(Ml − τ1√
n−1V
+ tf,1−α
2
√
ξ)
if ξ lies in the region Aξ =
{
ξ : Mu−Ml√
n−1V
< 2tf,1−α2
√
ξ
}
, and 0 otherwise since ϕ(ξ) < 0 when ξ /∈ Aξ . The power is∫
ϕ(ξ)I(ξ ∈ Aξ)g(ξ)dξ, and this leads to Equation (26).
Equation (27) is obtained as P ≈ ∫ ϕ(ξ)g(ξ)dξ, and the approximation error ∫ ϕ(ξ)I(ξ /∈ Aξ)g(ξ)dξ is negative. When n
is small, there is a large chance that ξ /∈ Aξ, leading to a large error in the power estimation.
Exact power formula for testing equivalence using ANCOVA with normally distributed covariates:
By using the same argument as that for Equation (26), we get the exact power equation
P =
∫ ∞
0
∫ (Mu−Ml)2
4σ2Vx(Υ˜)t
2
f,1−α/2
0
Φ( Mu − τ1√
σ2Vx(Υ˜)
− tf,1−α
2
√
ξ)− Φ( Ml − τ1√
σ2Vx(Υ˜)
+ tf,1−α
2
√
ξ)
 g(ξ)g(Υ˜)dξdΥ˜, (29)
where g(ξ) is the PDF of ξ = σˆ2/σ2 ∼ χ2f/f . In large samples, Equation (29) can be well approximated by
P = 1−
∫
Pr
t
f, (Mu − τ1)√
σ2Vx(Υ˜)
 < tf,1−α
2
 g(Υ˜)dΥ˜ − ∫ Pr
t
f, (τ1 −Ml)√
σ2Vx(Υ˜)
 < tf,1−α
2
 g(Υ˜)dΥ˜. (30)
Exact power formula for testing equivalence using two sample t test with unequal variances:
We extend Moser et al [8] exact approach to equivalence trials. Note that u = s21σ
2
0/(s
2
0σ
2
1) ∼ F (n1 − 1, n0 − 1) is
independent of ξ =
(n1−1) s
2
1
σ2
1
+(n0−1) s
2
0
σ2
0
n−2 ∼
χ2n−2
n−2 . Let
V (u) =
(n− 2)
(n1 − 1)u+ (n0 − 1) [
uσ21
n1
+
σ20
n0
], f(u) =
[
uσ21
n1
+
σ20
n0
]2
u2σ41
n21(n1−1) +
σ40
n20(n0−1)
, and h(u) = tf(u),1−α2
√
V (u)
σ21
n1
+
σ20
n0
.
Then
s21
n1
+
s20
n0
= ξ V (u). Let g(u) and g(ξ) denote respectively the PDF of u and ξ. The exact power is given by
P =
∫ ∞
0
∫ c(u)
0
Φ
 Mu − τ1√
σ21
n1
+
σ20
n0
− h(u)
√
ξ
− Φ
 Ml − τ1√
σ21
n1
+
σ20
n0
+ h(u)
√
ξ
 g(ξ)g(u)dξdu. (31)
where c(u) = (Mu−Ml)
2
4V (u) t2
f(u),1−α/2
. At a large sample size, the power can be approximated by
P = 1−
∫ Pr
t
n− 2, Mu − τ1√
σ21
n1
+
σ20
n0
 < h(u)
− Pr
t
n− 2, τ1 −Ml√
σ21
n1
+
σ20
n0
 < h(u)
 g(u)du. (32)
Setting (Ml,Mu) = (−∞, τ0) or (τ0,∞) into (32) yields the formula obtained by Moser et al [8], which is suitable for
superiority and NI tests.
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